How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation

A column by William Soliman, Ph.D., BCMAS, founder & CIO, White Manna Capital

In biotech, capital often appears to follow scientific breakthroughs and clinical milestones. But in the rapidly evolving world of RNA therapeutics, another force is quietly shaping which platforms attract funding and which struggle to move forward.

In his second “Soliman Says…” column, investor and biotech strategist William Soliman explores how subtle signals from early conversations with the U.S. FDA — particularly during pre-IND discussions — can ripple through venture capital firms, startup boardrooms, and financing decisions across the RNA ecosystem. Long before clinical data emerges, these informal regulatory cues are increasingly influencing how investors assess risk, allocate capital, and decide which RNA technologies are positioned to scale.

Behind many of today’s major RNA investments, Soliman argues, lies an often-unseen dynamic: the quiet but powerful role of early regulatory feedback in shaping the future of the field.

The Quiet Role Of Regulatory Signals In RNA Investment

Over the past decade, RNA therapeutics such as mRNA vaccines, siRNA, antisense oligonucleotides, and emerging RNA editing technologies have moved from being a scientific curiosity to one of the most important pillars of biotechnology investment. Venture capital firms, crossover investors, and public market funds have collectively poured billions of dollars into companies developing RNA based medicines. But behind many of those investment decisions is a force that rarely gets discussed publicly: informal regulatory feedback from the FDA.

Public FDA guidance certainly shapes the general framework for how drugs are developed. However, sophisticated investors increasingly pay close attention to what happens in early regulatory conversations, especially those that take place before an IND application is even filed. These early interactions, particularly pre-IND meetings, often provide subtle signals about regulatory expectations around manufacturing, comparability, and chemistry, manufacturing, and controls (CMC). Those signals can quietly influence which RNA platforms receive funding and which ones investors begin to view as too risky.

The FDA is not in the business of endorsing investment strategies. Yet in practice, regulatory expectations often ripple through venture capital firms and biotech boardrooms long before a therapy ever reaches clinical trials.

Pre-IND Meetings: The Earliest Signals Investors Watch

Pre-IND meetings represent one of the earliest opportunities for drug developers to obtain direct feedback from the FDA. During these meetings, sponsors can discuss preclinical data, manufacturing approaches, and plans for initial clinical trial design. The goal is to ensure that development programs align with regulatory expectations and reduce the likelihood of delays or clinical holds once an IND is submitted.

In reality, these conversations often serve another purpose as well. They generate early signals about how comfortable regulators are with a particular technology. Investors tend to listen carefully for shifts in tone from regulators. Questions about delivery systems, manufacturing reproducibility, or analytical characterization can act as early indicators of regulatory risk. Even subtle concerns raised during these discussions can quickly move into boardroom conversations about whether a company should continue investing heavily in a platform or reconsider its strategy.

Why Manufacturing And CMC Dominate RNA Regulatory Conversations

In the RNA sector, where technologies remain complex and manufacturing intensive, these signals carry significant weight. Unlike traditional small molecule drugs, RNA therapeutics rely heavily on advanced and often novel manufacturing processes. Lipid nanoparticle formulations, specialized nucleic acid chemistries, and evolving analytical techniques introduce significant variability into production.

Because of this, the FDA places strong emphasis on CMC during regulatory review. Regulators carefully examine factors such as identity, purity, potency, and safety when evaluating whether an investigational therapy is ready to move into human trials. For RNA companies, this creates a unique challenge. Many of them are innovating not only in the therapeutic modality itself but also in the manufacturing process that produces the therapy.

During early FDA discussions, reviewers often probe deeply into how well a company has characterized its RNA constructs, delivery systems, and analytical assays. Questions about potency assays, particle size distribution, or stability testing can signal whether a company’s manufacturing strategy appears robust or whether regulators believe there may be major hurdles ahead.

In many venture-backed RNA startups, board discussions following a pre-IND meeting now focus heavily on how well the company’s manufacturing approach aligns with emerging regulatory expectations. A positive regulatory tone can open the door to additional financing rounds. Negative feedback, on the other hand, can trigger an immediate reassessment of capital allocation.

Comparability: The Hidden Scaling Risk For RNA Platforms

Another area where regulatory expectations influence investment decisions is comparability. In biologics and advanced therapies, comparability refers to demonstrating that changes in manufacturing, such as scaling production or modifying processes, do not materially change the product’s safety or effectiveness. For RNA therapeutics, this challenge can be particularly acute. Early-stage companies may produce small batches in research settings, but commercial scale manufacturing requires different equipment, new purification processes, and more sophisticated analytical controls.

The FDA has made it clear that when manufacturing changes occur, companies must provide evidence that the product remains comparable to earlier clinical material. For investors, this introduces a strategic challenge. Some RNA companies raise capital based on the promise that their platforms can scale rapidly. But as development progresses, they may discover that regulatory expectations around comparability require additional studies or even new clinical data.

As a result, investors increasingly evaluate RNA startups not only on scientific innovation but also on the maturity of their manufacturing infrastructure. Companies that can demonstrate validated analytical assays and scalable production strategies early on are often viewed as carrying lower regulatory risk.

Early FDA Engagement As Investor Due Diligence

Because of these factors, experienced biotech investors frequently encourage RNA startups to engage with the FDA earlier than traditional drug developers might.

Early regulatory discussions allow companies to test their assumptions about manufacturing processes, analytical assays, and clinical development strategies before committing significant capital. These conversations can clarify expectations around IND-enabling studies and manufacturing controls, helping companies refine their development plans before applying.

For RNA platforms, this early alignment is especially valuable. Many technologies rely on novel delivery systems, proprietary chemistries, or innovative production methods that do not yet have clear regulatory precedent.

In these situations, even limited feedback from regulators can shape major strategic decisions. Companies may decide to invest in new manufacturing facilities, develop additional analytical assays, or adjust clinical trial design based on what they hear in early regulatory meetings.

In many ways, regulatory feedback becomes a form of technical due diligence that guides investment strategy.

How Regulatory Signals Shape Capital Flows Across RNA

Within venture capital and crossover investment circles, insights from early FDA interactions often spread informally through networks of board members, consultants, and regulatory experts. Even though the details of pre-IND meetings are confidential, investors often piece together broader regulatory trends. If multiple companies developing similar RNA technologies receive similar questions or concerns from regulators, investors may conclude that regulatory expectations for that modality are rising.

When this happens, capital flows can shift quickly across the RNA ecosystem. If regulators appear comfortable with certain delivery systems or manufacturing approaches, companies using those technologies may find it easier to attract funding. Conversely, platforms that appear to face greater regulatory uncertainty can struggle to secure follow-on financing. Over time, these dynamics help determine which RNA technologies mature into viable therapeutic platforms and which ones fail to gain traction.

Regulation As The Invisible Hand Of RNA Investment

The relationship between regulatory science and capital allocation is not new in biotechnology. However, the RNA sector illustrates how subtle regulatory signals —especially those delivered through informal early FDA interactions — can influence investment decisions long before clinical data becomes available.

For RNA therapeutics, the stakes are particularly high. Manufacturing complexity, rapidly evolving analytical tools, and continuous technological innovation mean that regulatory expectations are still taking shape in real time. In this environment, early FDA feedback through pre-IND discussions, comparability conversations, and manufacturing-related questions has become a powerful but largely invisible force shaping investment decisions. Investors may not openly cite regulatory tone when announcing funding rounds. But behind many major RNAA-driven financing decisions is a simple question that quietly shapes the outcome. And in today’s RNA driven biotechnology landscape, the answer to that question can determine whether a platform attracts billions in capital or slowly fades from the market.

About The Expert

William Soliman, Ph.D., is the founder & CEO of the Accreditation Council for Medical Affairs (ACMA) and the founder & CEO of White Manna Capital Partners, a biotech/pharma focused hedge fund. The ACMA is the leading life sciences accreditation, certification, and training company in the world and established the first ever certification standards for prior authorization, reimbursement, pharma sales, medical science liaisons, and medical affairs professionals.

Soliman is considered a pharmaceutical industry futurist. In March 2021, he testified before the United States Congress’ Energy and Commerce Health Subcommittee about the pharmaceutical industry and the importance of professional standards for those who directly engage healthcare providers, like sales representatives. Soliman is a former pharmaceutical executive who held leadership roles at several big pharma companies including Merck, Johnson & Johnson, AbbVie, and Gilead.

He is routinely featured on media outlets such as NewsNation, Fox News, ABC News, Forbes, Al Jazeera, Yahoo! Finance, Yahoo! Business TV, and more. Soliman received his Ph.D. from Columbia University and his bachelor’s degree from New York University.